(Q30429455)

21 June 2017

title

Improved adjuvanting of seasonal influenza vaccines: preclinical studies of MVA-NP+M1 coadministration with inactivated influenza vaccine (English)

1 reference

21 June 2017

1 reference

12

Sarah C Gilbert

0 references

Arjan van Laarhoven

3

object named as

Arjan van Laarhoven

0 references

Nigel J. Temperton

object named as

Nigel J Temperton

8

0 references

Teresa Lambe

11

object named as

Teresa Lambe

1 reference

21 June 2017

Bryan Charleston

10

0 references

author name string

Caitlin E Mullarkey

1

1 reference

21 June 2017

Amy Boyd

2

1 reference

21 June 2017

Eric A Lefevre

4

1 reference

21 June 2017

B Veronica Carr

5

1 reference

21 June 2017

Massimiliano Baratelli

6

1 reference

21 June 2017

Eleonora Molesti

7

1 reference

21 June 2017

Colin Butter

9

1 reference

21 June 2017

language of work or name

English

0 references

publication date

10 June 2013

1 reference

European Journal of Immunology

21 June 2017

published in

1 reference

21 June 2017

volume

43

1 reference

21 June 2017

issue

7

1 reference

21 June 2017

page(s)

1940-1952

1 reference

Heterosubtypic immunity to influenza A virus: where do we stand?

21 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242922

Efficacy studies of influenza vaccines: effect of end points used and characteristics of vaccine failures

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242922

Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242922

Induction of broadly neutralizing H1N1 influenza antibodies by vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242922

Cytotoxic T-cell immunity to influenza.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242922

Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242922

Declining T-cell immunity to influenza, 1977-82

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242922

Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242922

Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242922

Programming the magnitude and persistence of antibody responses with innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242922

Identification of H5N1-specific T-cell responses in a high-risk cohort in vietnam indicates the existence of potential asymptomatic infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242922

Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242922

Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242922

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242922

Alum-adjuvanted H5N1 whole virion inactivated vaccine (WIV) enhanced inflammatory cytokine productions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242922

MVA-based H5N1 vaccine affords cross-clade protection in mice against influenza A/H5N1 viruses at low doses and after single immunization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242922

Avian influenza vaccination in chickens and pigs with replication-competent adenovirus-free human recombinant adenovirus 5

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242922

The epidemiology and evolution of influenza viruses in pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242922

Novel protein and poxvirus-based vaccine combinations for simultaneous induction of humoral and cell-mediated immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242922

T cells primed by influenza virion internal components can cooperate in the antibody response to haemagglutinin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242922

Cell cooperation in antibody responses to influenza virus. I. priming of helper t cells by internal components of virion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242922

Universal vaccine against influenza virus: linking TLR signaling to anti-viral protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242922

Protective efficacy of several vaccines against highly pathogenic H5N1 avian influenza virus under experimental conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242922

Towards a universal vaccine for avian influenza: protective efficacy of modified Vaccinia virus Ankara and Adenovirus vaccines expressing conserved influenza antigens in chickens challenged with low pathogenic avian influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242922

Immune responses in pigs vaccinated with adjuvanted and non-adjuvanted A(H1N1)pdm/09 influenza vaccines used in human immunization programmes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242922

A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242922

Effective induction of high-titer antibodies by viral vector vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242922

A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242922

Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242922

A sensitive retroviral pseudotype assay for influenza H5N1-neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242922

The requirement for potent adjuvants to enhance the immunogenicity and protective efficacy of protein vaccines can be overcome by prior immunization with a recombinant adenovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242922

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242922

inferred from DOI database lookup

7 January 2021

based on heuristic

Avian influenza mucosal vaccination in chickens with replication-defective recombinant adenovirus vaccine

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242922

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/EJI.201242922

1 reference

21 June 2017

1 reference